Document is current

Article History

First Online: 15 April 2026

Declarations

:

: Dr. Buysse is a consultant for BeHealth (2016-current), Eisai, Inc (2019-current), Pear Therapeutics (2019-current), National Cancer Institute (2019-current), Idorsia Pharmaceuticals Ltd (2021-current), Sleep Number (2021-current), Synchronicity Pharma (2025-current); received research support from Sleep Number (2023–2025); is Board President at the Sleep Research Society (2025–2026); and receives compensation from the following intellectual property materials: the Pittsburgh Sleep Quality Index (1989-current), Pittsburgh Sleep Quality Index Addendum for PTSD (PSQI-A) (2005-current), Brief Pittsburgh Sleep Quality Index (B-PSQI) (2021-current), Daytime Insomnia Symptoms Scale (2007-current), Pittsburgh Sleep Diary (1994-current), Insomnia Symptom Questionnaire (2009-current), RU_SATED (copyrights held by University of Pittsburgh) (2021-current), the Consensus Sleep Diary (copyright held by Ryerson University) (2012-current).Dr. Arnedt consulted for Purdue Pharma (2021–2022), Eisai, Inc. (2021–2022), Idorsia Pharmaceuticals Ltd (2022), and received compensation from the following intellectual property materials: telephone-delivered insomnia therapy treatment manuals (copyright held by University of Michigan) (2013–2024).Dr. Fernandez-Mendoza serves on the Society of Behavioral Sleep Medicine’s guideline development expert panel (2023-current) and on the Sleep Research Society’s Board of Directors (2024-current).Dr. Falck-Ytter is a paid consultant for the AASM and an affiliated member of the United States Grading of Recommendations Assessment, Development and Evaluation Network and the Evidence Foundation.Dr. Hyer is employed by the AASM.Ms. Kazmi is a former employee of the AASM who was employed by the AASM at the time of her work on this guideline.Dr. Singh serves on the AASM Guideline Advisory Panel; the Hypersomnia Foundation’s medical advisory board (2018-current); has served on the Society of Anesthesia and Sleep Medicine Board of Directors (SASM) (2020-current) and is President-elect of SASM (2024–2026).Dr. Wickwire is a consultant for Nox Health (2023-current) and ResMed Corp. (2022-current); has served as a consultant for Axsome Therapeutics, Eisai, Inc., Ensodata, Idorsia Pharmaceuticals Ltd, Merck Sharp & Dohme Corporation, and Primasun; receives research support from Merck Sharp & Dohme Corporation (2020-current), and ResMed Foundation (2022–2027); owns stock in WellTap (2011-current); and serves on the AASM Board of Directors (2022-current).Dr. Buenaver, Dr. Chang, Dr. Patel, and Dr. Zhou have no relevant conflicts of interest to disclose.